VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...

Pfizer and Arvinas are poised to bring the third oral selective oestrogen receptor degrader (SERD) to market in the US, after ...

Arvinas’ fair value estimate sits at US$14.88 per share, with the latest model keeping this price target unchanged. That stability comes as Street research remains split, with analysts clustering in ...

Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...

Pfizer (PFE) stock and Arvinas (ARVN) stock are in focus as the FDA approves the companies' breast cancer drug, Veppanu. Read ...

Arvinas and Pfizer received approval from the Food and Drug Administration for Veppanu, the companies' jointly developed advanced breast cancer treatment. Arvinas said Friday the FDA approved the drug ...

May 1 (Reuters) - The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' breast cancer drug for ...

Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for ...

The FDA has approved the first proteolysis-targeting chimera for any oncologic indication. Vepdegestrant (Veppanu, Arvinas ...

The decision also marks the FDA’s first approval of a PROTAC therapy, a type of targeted protein-degrading drug. ・The approval is based on a Phase 3 trial, in which Veppanu reduced the risk of disease ...

About two and a half years after originating the role of chief commercial officer at Arvinas, John Northcott is leaving his post at the biotech. The change is effective immediately, according to ...

The health news this week highlights key legal and medical developments. Danco Laboratories is challenging a court's decision ...